July 1st 2020, 5:32pm
Bradley J. Monk, MD, FACS, FACOG, discusses the utility of tisotumab vedotin in recurrent cervical cancer.
June 30th 2020, 4:19pm
The antibody-drug conjugate tisotumab vedotin induced clinically meaningful and durable responses in patients who have relapsed or progressed on or after previous treatment for recurrent or metastatic cervical cancer.
June 26th 2020, 5:37pm
The field of gynecologic oncology gained a number of important updates at the 2020 ASCO Virtual Scientific Program. As part of the ASCO Direct Highlights webcast, Jubilee Brown, MD, provided insight on key trials that were presented at the program.
June 25th 2020, 12:15am
Endometrial cancer tumor types are traditionally categorized through a combination of histologic molecular subtyping and clinical staging; however, the incorporation of new diagnostic algorithms may have clinical implications for treatment.
June 24th 2020, 11:50am
David O'Malley, MD, discusses the utility of mirvetuximab soravtansine in ovarian cancer.
June 23rd 2020, 5:15pm
R. Wendel Naumann, MD, discusses the early results reported with STRO-002, the hope for this agent in the ovarian cancer space, and the next steps for this research.
June 23rd 2020, 2:30pm
Pembrolizumab demonstrated modest clinical activity in patients with advanced recurrent ovarian cancer.
June 16th 2020, 11:49pm
Brian M. Slomovitz, MD, discusses sequencing strategies for endometrial cancer.
June 10th 2020, 11:56pm
The combination of nivolumab plus ipilimumab was found to induce a superior response rate and longer progression-free survival compared with nivolumab alone in patients with persistent or recurrent epithelial ovarian cancer.
June 10th 2020, 9:00pm
Ursula A. Matulonis, MD, discusses final data from the phase 2 KEYNOTE-100 trial with pembrolizumab (Keytruda) in advanced recurrent ovarian cancer.
